Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tarsus Pharmaceuticals (TARS) Free Cash Flow (2020 - 2025)

Tarsus Pharmaceuticals (TARS) has 6 years of Free Cash Flow data on record, last reported at $13.0 million in Q4 2025.

  • For Q4 2025, Free Cash Flow rose 154.75% year-over-year to $13.0 million; the TTM value through Dec 2025 reached -$22.3 million, up 73.63%, while the annual FY2025 figure was -$22.3 million, 73.63% up from the prior year.
  • Free Cash Flow reached $13.0 million in Q4 2025 per TARS's latest filing, down from $16.3 million in the prior quarter.
  • Across five years, Free Cash Flow topped out at $20.4 million in Q2 2021 and bottomed at -$38.0 million in Q4 2023.
  • Average Free Cash Flow over 5 years is -$13.5 million, with a median of -$15.5 million recorded in 2022.
  • Peak YoY movement for Free Cash Flow: surged 892.83% in 2021, then tumbled 492.09% in 2023.
  • A 5-year view of Free Cash Flow shows it stood at -$12.7 million in 2021, then grew by 17.24% to -$10.5 million in 2022, then crashed by 261.04% to -$38.0 million in 2023, then skyrocketed by 37.6% to -$23.7 million in 2024, then skyrocketed by 154.75% to $13.0 million in 2025.
  • Per Business Quant database, its latest 3 readings for Free Cash Flow were $13.0 million in Q4 2025, $16.3 million in Q3 2025, and -$30.9 million in Q2 2025.